RT @synovialjoints: Guselkumab 100 mg Q4W and Q8W provided robust and sustained benefits to patients with active PsA acr
Tweet Content
Guselkumab 100 mg Q4W and Q8W provided robust and sustained benefits to patients with active PsA across multiple domains. Listen to my interview with Prof. Laura Coates on this and other emerging treatments in PsA here https://t.co/PSbJ0HA5a6
@RheumNow #ACR21 Abstr#1335 https://t.co/WzBOYGOxAA
Links
Updates on New Treatments for SpA: Drs. Antoni Chan and Laura Coates | RheumNow
https://bit.ly/3BUCJ8B
Show on Archive Page
On
Display in Search Results
On
PDQ
Off